Change in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse Outcome

Global Spine Journal - Tập 6 Số 7 - Trang 650-659 - 2016
Jashvant Poeran1, Mathias Opperer2, Rehana Rasul1, Madhu Mazumdar1, Federico P. Girardi3, Alexander P. Hughes3, Stavros G. Memtsoudis2, Vassilios I. Vougioukas4
1Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2Department of Anesthesiology, Hospital for Special Surgery, New York, New York, United States
3Department of Orthopedic Surgery, Hospital for Special Surgery, New York, New York, United States
4Department of Neurosurgery, Albert Ludwig University of Freiburg, Freiburg, Germany

Tóm tắt

Study Design Retrospective cohort study. Objective The U.S. Food and Drug Administration issued a warning in 2008 against off-label bone morphogenetic protein (BMP-2) use. We aimed to determine (off-label) BMP-2 use in two periods and associations with complications. Methods We included 340,393 patients undergoing spinal fusions from the Premier Perspective database (2006 to 2012). BMP-2 use was determined from billing in 2006 to 2008 versus 2009 to 2012. Outcomes included revisions, length of hospital stay (LOHS), and cost of hospital stay (COH). Multilevel regressions measured associations between BMP-2 and outcomes; odds ratios (ORs) and 95% confidence intervals (CIs) are reported. Results BMP-2 use decreased from 18.7% in 2006 to 11.5% in 2012. Off-label use remains but is decreasing, particularly for cervical anterior (5.1 versus 2.0%) and cervical posterior procedures (15.3 versus 8.5%; both p < 0.01 comparing 2006 to 2008 with 2009 to 2012). BMP-2 remains associated with increased LOHS (median 2 versus 3 days; both periods) and COH (median $15,455 versus $27,881 in 2006 to 2008; $17,007 versus $30,331 in 2009 to 2012). Adjusted ORs for the association between BMP-2 and adverse outcomes were generally lower in 2009 to 2012 compared with 2006 to 2008. Most notably, we demonstrate lower ORs for revision after cervical fusions in 2009 to 2012 (OR 1.67, CI 1.01 to 2.78) compared with 2006 to 2008 (OR 2.43, CI 1.66 to 3.54). Conclusions Using a previously untapped data source, we show decreased (off-label) BMP-2 use in spinal fusions, particularly in cervical fusions. Although there was a tendency of decreased odds in 2009 to 2012, higher resource utilization and odds for complications remain in patients using BMP-2. A national registry or prospective observational studies will benefit the ongoing discussion.

Từ khóa


Tài liệu tham khảo

10.1001/jama.2009.956

10.1097/BRS.0b013e31820cccfb

U.S. Food and Drug Administration InFuseTM Bone Graft/LT-CAGETM lumbar tapered fusion device-P000058, 2002 Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=P000058 . Accessed January 23, 2014

10.1055/s-0031-1298616

10.4103/2152-7806.114813

10.1097/BRS.0000000000000004

10.1016/j.spinee.2013.11.042

10.1097/BRS.0b013e3181ecf6e4

10.1097/BRS.0b013e31828f494c

U.S. Food and Drug Administration FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion, 2008 Available at: http://www.fda.gov/medicaldevices/safety/alertsandnotices/publichealthnotifications/ucm062000.htm . Accessed January 23, 2014

10.1016/j.spinee.2011.04.023

U.S. Food and Drug Administration OP-1TM-H010002, 2001 Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm085026.htm . Accessed January 23, 2014

Premier, Inc Premier Perspective Database Available at: https://www.premierinc.com/transforming-healthcare/healthcare-performance-improvement/premier-research-services/ . Accessed January 2, 2014

10.1371/journal.pone.0087382

10.1016/j.spinee.2012.10.035

10.1007/s00586-012-2298-8

10.1016/0895-4356(92)90133-8

10.3402/ijch.v61i3.17459

10.1016/j.spinee.2006.04.010

10.1007/s00586-007-0351-9

10.1136/bmj.f3981

10.1016/j.spinee.2011.05.009

10.1001/jama.2011.1459

10.7326/0003-4819-158-12-201306180-00005

10.7326/0003-4819-158-12-201306180-00006

10.2106/JBJS.L.01483

10.1007/s00586-009-1248-6

10.1097/BRS.0b013e3181c71447

10.3310/hta11300

10.1016/j.spinee.2007.03.004

10.1002/jor.22160

10.1002/pds.2057

10.5435/00124635-201209000-00001

Thông tin
Thông tin xuất bản

Global Spine Journal

Tập 6 Số 7

650-659

Thông tin tác giả